PD-1/PD-L1-IN-29

• UNSPSC Description:

  PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity[1].

• Target Antigen:

  PD-1/PD-L1

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/pd-1-pd-l1-in-29.html

• Solubility:

  DMSO : 66.67 mg/mL (ultrasonic;adjust pH to 2 with 1M HCl)

• Smiles:

  OC[C@H](NCC1=CC2=C(C=C1OC)C(N(C2=O)C3=C(C(C4=CC=CC=C4)=CC=C3)C)=O)C(O)=O

• Molecular Weight:

  460.48

• References & Citations:

  [1]Chengliang Sun, et al. Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. J Med Chem. 2022 Dec 29.

• Shipping Conditions:

  Blue Ice

• Clinical Information:

  No Development Reported

• CAS Number:

  2665734-13-2